Literature DB >> 11258781

Detection and prediction of micrometastasis in the lymph nodes of patients with pN0 gastric cancer.

A Nakajo1, S Natsugoe, S Ishigami, M Matsumoto, S Nakashima, S Hokita, M Baba, S Takao, T Aikou.   

Abstract

BACKGROUND: The clinicopathologic significance of micrometastasis (MM) and tumor cell microinvolvement (TCM) in regional lymph nodes as identified by immunohistochemical staining for cytokeratin expression was evaluated in patients with node-negative gastric cancer.
METHODS: MM was defined as tumor cells with stromal reaction, and TCM was defined as individual tumor cells without stromal reaction. We investigated 1761 lymph nodes obtained from 67 gastric cancer patients whose diagnosis showed no lymph node metastasis by routine histological examination. The depth of tumor invasion was T1 (submucosa) in 33 patients and T2 (muscularis propria and subserosa) in 34 patients. The lymph nodes were examined immunohistochemically for the presence of tumor cells using anti-cytokeratin AE1/AE3 monoclonal antibody. Both the biopsy tumor specimens obtained prior to surgery and the resected primary tumors were immunostained with E-cadherin (E-cad) monoclonal antibody.
RESULTS: Thirty (1.5%) of the 1761 lymph nodes showed MM and/or TCM. MM with or without TCM was found in 10 patients, and TCM alone was found in 4 patients; 6 (18.2%) of the 33 patients with T1 tumor and 8 (23.5%) of the 34 patients with T2 tumor had occult lymph node metastasis. The 5-year survival rate was worse among those with MM with or without TCM, than among those without MM. Nearly all of the patients with MM and/or TCM had reduced or negative E-cad expression in the primary tumor.
CONCLUSIONS: We demonstrated that the incidence of MM and/or TCM in the lymph nodes of patients with gastric cancer is quite high, and that such metastasis is associated with the prognosis of patients with pN0. Examination of E-cad expression in biopsy tumor specimens may be useful for predicting MM and/or TCM.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11258781     DOI: 10.1007/s10434-001-0158-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  30 in total

1.  Prognostic impact of venous invasion in stage IB node-negative gastric cancer.

Authors:  Ippeita Araki; Kei Hosoda; Keishi Yamashita; Natsuya Katada; Shinichi Sakuramoto; Hiromitsu Moriya; Hiroaki Mieno; Akira Ema; Shiro Kikuchi; Tetuo Mikami; Masahiko Watanabe
Journal:  Gastric Cancer       Date:  2014-04-01       Impact factor: 7.370

2.  Entire-volume serial histological examination for detection of micrometastases in lymph nodes of colorectal cancers.

Authors:  Masaki Hata; Junji Machi; Jonathan Mamou; Eugene T Yanagihara; Emi Saegusa-Beecroft; Gregory K Kobayashi; Clifford C M Wong; Conway Fung; Ernest J Feleppa; Kazuhiro Sakamoto
Journal:  Pathol Oncol Res       Date:  2011-04-15       Impact factor: 3.201

3.  The clinical importance of micrometastases within the lymphatic system in patients after total gastrectomy.

Authors:  Arkadiusz Spychała; Dawid Murawa; Konstanty Korski
Journal:  Rep Pract Oncol Radiother       Date:  2011-10-14

4.  Intraoperative diagnosis of lymph node metastasis by transcription-reverse transcription concerted reaction assay in gastric cancer.

Authors:  Ryouichi Hirayama; Akiyoshi Seshimo; Kunitomo Miyake; Masako Nishizawa; Shingo Kameoka
Journal:  Int J Clin Oncol       Date:  2013-06-14       Impact factor: 3.402

5.  Do we have enough evidence for expanding the indications of ESD for EGC?

Authors:  Hang Lak Lee; Chang Hwan Choi; Dae Young Cheung
Journal:  World J Gastroenterol       Date:  2011-06-07       Impact factor: 5.742

6.  Occult Tumour Cells in Lymph Nodes from Gastric Cancer Patients: Should Isolated Tumour Cells Also Be Considered?

Authors:  A Tavares; X Wen; J Maciel; F Carneiro; M Dinis-Ribeiro
Journal:  Ann Surg Oncol       Date:  2020-05-04       Impact factor: 5.344

Review 7.  Detection and clinical implications of minimal residual disease in gastro-intestinal cancer.

Authors:  Fabian Wolfrum; Ilka Vogel; Fred Fändrich; Holger Kalthoff
Journal:  Langenbecks Arch Surg       Date:  2005-07-01       Impact factor: 3.445

8.  Clinical validity of the expanded criteria for endoscopic resection of undifferentiated-type early gastric cancer based on long-term outcomes.

Authors:  Shiro Oka; Shinji Tanaka; Makoto Higashiyama; Norifumi Numata; Yoji Sanomura; Shigeto Yoshida; Koji Arihiro; Kazuaki Chayama
Journal:  Surg Endosc       Date:  2013-10-11       Impact factor: 4.584

9.  Recurrence of a pT2N0cM0 Lower Third Gastric Cancer with No. 6 Lymph Node Micrometastasis after R0 Extended Surgery. Should Adjuvant Therapy be Performed in Conventionally Node-Negative but Micrometastasis-Positive pT2 Gastric Cancer?

Authors:  Konstantinos Blouhos; Konstantinos A Boulas; Konstantinos Tsalis; Nikolaos Barettas; Michail Aftzoglou; Anestis Hatzigeorgiadis
Journal:  J Gastrointest Cancer       Date:  2017-03

10.  Previstage GCC test for staging patients with colorectal cancer.

Authors:  Alex Mejia; Scott A Waldmana
Journal:  Expert Rev Mol Diagn       Date:  2008-09       Impact factor: 5.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.